Since then, four additional anti-CD19 CAR-T-based anti-cancer therapies and one anti-B-cell maturation antigen (BCMA) CAR T product have been approved for the treatment of B-cell lymphomas/leukemias and multiple myeloma [172,174,175], respectively. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.